Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel TherapeuticsBTAI +4.45%10 3-1 Month Momentum % is -32.10% as of Sep. 02, 2026. GuruFocus rates BTAI with a GF Score™ of 10/100 and a GF Value™ of $0.54 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,024 Drug Manufacturers companies, BioXcel Therapeutics ranks worse than 92.38% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), BioXcel Therapeutics's 3-1 Month Momentum % is -32.10%.
The industry rank for BioXcel Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
BTAI's 3-1 Month Momentum % is ranked worse than 92.38% of 1024
companies
in the Drug Manufacturers industry
Industry Median: -3.385
vs BTAI: -32.10
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioXcel Therapeutics 3-1 Month Momentum % Related Terms
BTAI vs YCBD, APUS, LVRLF: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a 3-1 Month Momentum % of -32.10% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #946 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 92.4%.
Is BioXcel Therapeutics' 3-1 Month Momentum % too high?
BioXcel Therapeutics' current 3-1 Month Momentum % is -32.10%. Based on the distribution chart, BioXcel Therapeutics ranks #946 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 10/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' 3-1 Month Momentum % compare to YCBD and APUS?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #946 out of 1024 companies for 3-1 Month Momentum %. This places BioXcel Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current 3-1 Month Momentum % is -32.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Possible Value Trap. The stock's GF Value™ is $0.54, compared to a current price of $0.14 — trading 73.5% below its estimated fair value. The current 3-1 Month Momentum % is -32.10%. BioXcel Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current 3-1 Month Momentum % is -32.10% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be undervalued.
The current stock price of $0.14 is trading 73.5% below its estimated GF Value™ of $0.54.
GuruFocus considers BioXcel Therapeutics to be Possible Value Trap.
Key valuation signals for BTAI:
3-1 Month Momentum %: -32.10%
GF Value™: $0.54 vs. price of $0.14 (73.5% below fair value)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
10GF Score
Get the complete analysis for BTAI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
